GenoFocus, Inc.

A187420

KR7187420005

Commodity Chemicals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4,220 ^KRW	+0.60%		+1.93%	+8.07%

2023	GenoFocus, Inc. agreed to acquire an additional 13.38% stake in GF Fermentech Co., Ltd. for KRW 5.9 billion	CI
2023	GenoFocus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

GenoFocus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 23, 2023 at 04:46 am EDT

GenoFocus, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was KRW 269.37 million compared to KRW 708.69 million a year ago. Net loss was KRW 12,968.03 million compared to KRW 6,816.59 million a year ago.

Basic loss per share from continuing operations was KRW 576 compared to KRW 304 a year ago. Diluted loss per share from continuing operations was KRW 576 compared to KRW 304 a year ago. Basic loss per share was KRW 576 compared to KRW 304 a year ago.

Latest news about GenoFocus, Inc.

GenoFocus, Inc. agreed to acquire an additional 13.38% stake in GF Fermentech Co., Ltd. for KRW 5.9 billion	23-07-16	CI
GenoFocus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
GenoFocus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
GenoFocus, Inc.(KOSDAQ:A187420) dropped from S&P Global BMI Index	22-09-19	CI
GenoFocus, Inc. announced that it expects to receive KRW 23.2 billion in funding	22-06-27	CI
GenoFocus, Inc.(KOSDAQ:A187420) added to S&P Global BMI Index	21-09-20	CI
GenoFocus, Inc. announced that it has received KRW 10 billion in funding	20-08-23	CI
GenoFocus, Inc. announced that it expects to receive KRW 10 billion in funding	20-08-20	CI
GenoFocus, Inc. to Enter into Co-Development Agreement with Eight Organizations for COVID-19	20-06-02	CI
GenoFocus, Inc.(KOSDAQ:A187420) dropped from S&P Global BMI Index	19-09-23	CI
GenoFocus, Inc. acquired 65.35% stake in Sungwun Bio Co., Ltd. from Sungwun Pharmacopia Co. Ltd. for KRW 5 billion.	17-03-09	CI
Geno Focus, Inc. announced that it has received KRW 30.8 billion in funding from Shinhan Capital, Investment Arm and other investors	16-10-31	CI
Geno Focus, Inc. announced that it expects to receive KRW 30.8 billion in funding from Shinhan Capital, Investment Arm and other investors	16-10-26	CI
Geno Focus, Inc.(KOSDAQ:A187420) added to S&P Global BMI Index	15-09-21	CI
Geno Focus, Inc. has completed an IPO in the amount of KRW 13.20 billion.	15-05-22	CI
Geno Focus, Inc. has filed an IPO.	14-12-18	CI

Chart GenoFocus, Inc.

Duration

Period

More charts

Company Profile

GenoFocus, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of enzymes. The Company mainly manufactures catalases, lactase, phytases and other enzymes. The catalases are mainly used for industry, including processing of semiconductors, petroleum and propylene oxide, medical therapeutics, food processing, contact-lens and other industries. The lactases are mainly used for food processing including processing of milk, yogurt and milk serum. The phytases are mainly used for processing of animal feed. And the Company is exploring new businesses, engaged in development of other enzymes including therapeutic enzymes, chemical agents and others.

Sector

Commodity Chemicals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Commodity Chemicals

	1st Jan change	Capi.
GENOFOCUS, INC.	+8.07%	69.41M
AIR LIQUIDE	+2.80%	103B
SAUDI BASIC INDUSTRIES CORPORATION	+1.20%	67.05B
PT CHANDRA ASRI PACIFIC TBK	+44.29%	40.4B
WANHUA CHEMICAL GROUP CO., LTD.	+15.99%	38.64B
LYONDELLBASELL INDUSTRIES N.V.	+3.62%	32.41B
WESTLAKE CORPORATION	+6.20%	19.17B
NINGXIA BAOFENG ENERGY GROUP CO., LTD.	+12.32%	16.76B
HENGLI PETROCHEMICAL CO.,LTD.	+17.69%	15.07B
RONGSHENG PETROCHEMICAL CO., LTD.	+8.31%	14.82B